Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems.
HCV protease
Hepatitis C virus (HCV)
Hepatitis E virus (HEV)
co-infection
human hepatocytes
human liver chimeric mice
sofosbuvir
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
08 03 2022
08 03 2022
Historique:
received:
14
01
2022
revised:
04
03
2022
accepted:
04
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Hepatitis C virus (HCV) constitutes a global health problem, while hepatitis E virus (HEV) is the major cause of acute viral hepatitis globally. HCV/HEV co-infections have been poorly characterized, as they are hampered by the lack of robust HEV cell culture systems. This study developed experimental models to study HCV/HEV co-infections and investigate viral interference in cells and humanized mice. We used state-of-the art human hepatocytes tissue culture models to assess HEV and HCV replication in co- or super-transfection settings. Findings were confirmed by co- and super-infection experiments in human hepatocytes and in vivo in human liver chimeric mice. HEV was inhibited by concurrent HCV replication in human hepatocytes. This exclusion phenotype was linked to the protease activity of HCV. These findings were corroborated by the fact that in HEV on HCV super-infected mice, HEV viral loads were reduced in individual mice. Similarly, HCV on HEV super-infected mice showed reduced HCV viral loads. Direct interference of both viruses with HCV NS3/4A as the determinant was observed. In vivo, we detected reduced replication of both viruses after super-infection in individual mice. These findings provide new insights into the pathogenesis of HCV-HEV co-infections and should contribute to its clinical management in the future.
Sections du résumé
BACKGROUND
Hepatitis C virus (HCV) constitutes a global health problem, while hepatitis E virus (HEV) is the major cause of acute viral hepatitis globally. HCV/HEV co-infections have been poorly characterized, as they are hampered by the lack of robust HEV cell culture systems. This study developed experimental models to study HCV/HEV co-infections and investigate viral interference in cells and humanized mice.
METHODS
We used state-of-the art human hepatocytes tissue culture models to assess HEV and HCV replication in co- or super-transfection settings. Findings were confirmed by co- and super-infection experiments in human hepatocytes and in vivo in human liver chimeric mice.
RESULTS
HEV was inhibited by concurrent HCV replication in human hepatocytes. This exclusion phenotype was linked to the protease activity of HCV. These findings were corroborated by the fact that in HEV on HCV super-infected mice, HEV viral loads were reduced in individual mice. Similarly, HCV on HEV super-infected mice showed reduced HCV viral loads.
CONCLUSION
Direct interference of both viruses with HCV NS3/4A as the determinant was observed. In vivo, we detected reduced replication of both viruses after super-infection in individual mice. These findings provide new insights into the pathogenesis of HCV-HEV co-infections and should contribute to its clinical management in the future.
Identifiants
pubmed: 35326378
pii: cells11060927
doi: 10.3390/cells11060927
pmc: PMC8946046
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : German Federal Ministry of Health
ID : ZMVI1-2518FSB705
Organisme : Research Foundation - Flanders
ID : G047417N
Organisme : Research Foundation - Flanders
ID : VirEOS 30981113
Références
Gastroenterology. 2009 Oct;137(4):1448-58
pubmed: 19632233
J Virol. 2013 May;87(10):6031-6
pubmed: 23468481
Hepatology. 2005 Apr;41(4):847-56
pubmed: 15791625
Viruses. 2016 Aug 06;8(8):
pubmed: 27509518
J Infect Dis. 2009 Jul 1;200(1):48-56
pubmed: 19473098
PLoS One. 2012;7(4):e35759
pubmed: 22558217
Curr Top Microbiol Immunol. 2013;369:263-88
pubmed: 23463205
Gastroenterology. 2017 Jan;152(1):300-301
pubmed: 27883881
J Virol. 2010 Nov;84(21):11264-78
pubmed: 20739520
J Virol. 2007 May;81(9):4591-603
pubmed: 17301154
EMBO Mol Med. 2017 Jun;9(6):816-834
pubmed: 28360091
J Clin Virol. 2017 Mar;88:39-45
pubmed: 28160727
Lancet Gastroenterol Hepatol. 2017 May;2(5):325-336
pubmed: 28397696
Gastroenterology. 2013 Dec;145(6):1404-13.e1-10
pubmed: 23973767
J Hepatol. 2014 Nov;61(1 Suppl):S45-57
pubmed: 25086286
Transfus Med Hemother. 2019 Apr;46(2):95-103
pubmed: 31191195
Gut. 2017 May;66(5):920-929
pubmed: 27006186
J Infect Public Health. 2020 Jan;13(1):149-150
pubmed: 31235341
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2132-9
pubmed: 26787701
Viruses. 2019 May 28;11(6):
pubmed: 31141919
Environ Sci Pollut Res Int. 2020 Sep;27(27):33659-33667
pubmed: 32533486
J Hepatol. 2016 May;64(5):1033-1040
pubmed: 26805671
Liver Int. 2020 Mar;40(3):522-529
pubmed: 31815353
N Engl J Med. 2014 Mar 20;370(12):1111-20
pubmed: 24645943
Antiviral Res. 2019 Oct;170:104570
pubmed: 31362004
J Infect. 2015 Jun;70(6):624-30
pubmed: 25452042
J Hepatol. 2018 Jun;68(6):1256-1271
pubmed: 29609832
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1731-1741
pubmed: 31896581
Intervirology. 2007;50(4):281-6
pubmed: 17570930
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2992-7
pubmed: 15710891
J Hepatol. 2017 Sep;67(3):471-479
pubmed: 28412294
Gastroenterology. 2012 May;142(6):1388-1397.e1
pubmed: 22537448
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e471-e477
pubmed: 33867444
J Virol. 2010 May;84(10):5404-14
pubmed: 20200238
Methods. 2013 Feb;59(2):233-48
pubmed: 23009812
Transpl Int. 2017 Mar;30(3):318-319
pubmed: 27896862
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
Proc Natl Acad Sci U S A. 2006 May 9;103(19):7408-13
pubmed: 16651538
PLoS Pathog. 2009 Jan;5(1):e1000269
pubmed: 19148281
Hepatology. 2012 Apr;55(4):988-97
pubmed: 22121109
Gastroenterology. 2016 Jan;150(1):82-85.e4
pubmed: 26408347
Clin Infect Dis. 2020 Aug 22;71(5):1204-1211
pubmed: 31793638
Antiviral Res. 2019 Mar;163:34-49
pubmed: 30653997
BMC Infect Dis. 2005 May 17;5:36
pubmed: 15904504
J Virol Methods. 2003 Jun 30;110(2):201-9
pubmed: 12798249
Hepatology. 2015 Sep;62(3):702-14
pubmed: 25999047
Nat Rev Dis Primers. 2017 Mar 02;3:17006
pubmed: 28252637
mBio. 2018 May 8;9(3):
pubmed: 29739903
Semin Liver Dis. 2013 Feb;33(1):62-70
pubmed: 23564390
J Hepatol. 2020 Sep;73(3):696-699
pubmed: 32624195
Cell Host Microbe. 2014 Feb 12;15(2):190-202
pubmed: 24528865
Nat Rev Gastroenterol Hepatol. 2018 Feb;15(2):96-110
pubmed: 29162935
Front Immunol. 2018 May 14;9:1032
pubmed: 29867998
J Virol. 2016 Nov 14;90(23):10670-10681
pubmed: 27654291
J Gen Virol. 2010 Nov;91(Pt 11):2782-93
pubmed: 20631091
Nat Biotechnol. 2010 Feb;28(2):167-71
pubmed: 20118917
Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):122-132
pubmed: 27924080